Completed PHASE3 INTERVENTIONAL 2-arm NCT00275132

Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer (TOPICAL)

A Randomised, Placebo-Controlled Trial of Erlotinib in Patients With Advanced NSCLC Unsuitable for Chemotherapy

Sponsor: Cancer Research UK

Interventions Matched placebo erlotinib hydrochloride

Updated 5 times since 2017 Last updated: Dec 1, 2014 Started: Apr 30, 2005 Primary completion: Apr 30, 2009 Completion: Apr 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00275132, this PHASE3 trial focuses on Lung Cancer and remains completed. Sponsored by Cancer Research UK, it has been updated 5 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Apr 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cancer Research UK
Roche Pharma AG
University College, London

Data source: University College, London

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom